456 related articles for article (PubMed ID: 18848503)
81. [Pharmacotherapy of inflammatory bowel disease].
Jojić N
Acta Chir Iugosl; 2000; 47(1-2):51-5. PubMed ID: 10953366
[TBL] [Abstract][Full Text] [Related]
82. Non-calculus suppurative cholangitis in Danish patients with inflammatory bowel disease.
Rasmussen HH; Nørgård B; Olsen ML; Fonager K; Sørensen HT
Hepatogastroenterology; 2005; 52(61):115-8. PubMed ID: 15783009
[TBL] [Abstract][Full Text] [Related]
83. Inflammatory bowel disease: management issues during pregnancy.
Ferrero S; Ragni N
Arch Gynecol Obstet; 2004 Sep; 270(2):79-85. PubMed ID: 12721680
[TBL] [Abstract][Full Text] [Related]
84. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
Jakobovits SL; Jewell DP; Travis SP
Aliment Pharmacol Ther; 2007 May; 25(9):1055-60. PubMed ID: 17439506
[TBL] [Abstract][Full Text] [Related]
85. Prevention of acute adverse events related to infliximab infusions in pediatric patients.
Lahdenne P; Wikström AM; Aalto K; Kolho KL
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):785-90. PubMed ID: 20535789
[TBL] [Abstract][Full Text] [Related]
86. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
Duburque C; Lelong J; Iacob R; Seddik M; Desreumaux P; Fournier C; Wallaert B; Cortot A; Colombel JF
Aliment Pharmacol Ther; 2006 Sep; 24(5):851-8. PubMed ID: 16918890
[TBL] [Abstract][Full Text] [Related]
87. Safety of infliximab in children with IBD: the experience of an academic center in WV.
Northcutt M; Al-Subu A; Bella B; Elitsur Y
W V Med J; 2014; 110(3):26-9. PubMed ID: 24984403
[TBL] [Abstract][Full Text] [Related]
88. Infliximab treatment for symptomatic Crohn's disease strictures.
Pelletier AL; Kalisazan B; Wienckiewicz J; Bouarioua N; Soulé JC
Aliment Pharmacol Ther; 2009 Feb; 29(3):279-85. PubMed ID: 19035967
[TBL] [Abstract][Full Text] [Related]
89. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.
Mackey AC; Green L; Liang LC; Dinndorf P; Avigan M
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):265-7. PubMed ID: 17255842
[TBL] [Abstract][Full Text] [Related]
90. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis.
Simonini G; Zannin ME; Caputo R; Falcini F; de Martino M; Zulian F; Cimaz R
Rheumatology (Oxford); 2008 Oct; 47(10):1510-4. PubMed ID: 18676502
[TBL] [Abstract][Full Text] [Related]
91. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
Yamamoto-Furusho JK; Uzcanga LF
Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
[TBL] [Abstract][Full Text] [Related]
92. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
93. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
94. Infliximab-induced psoriasis in children with inflammatory bowel disease.
Hiremath G; Duffy L; Leibowitz I
J Pediatr Gastroenterol Nutr; 2011 Feb; 52(2):230-2. PubMed ID: 21240020
[TBL] [Abstract][Full Text] [Related]
95. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease.
Ananthakrishnan AN; McGinley EL; Binion DG
Gut; 2008 Feb; 57(2):205-10. PubMed ID: 17905821
[TBL] [Abstract][Full Text] [Related]
96. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England.
Russo EA; Harris AW; Campbell S; Lindsay J; Hart A; Arebi N; Milestone A; Tsai HH; Walters J; Carpani M; Westaby D; Thillainayagam A; Bansi D; Ghosh S
Aliment Pharmacol Ther; 2009 Feb; 29(3):308-14. PubMed ID: 19035973
[TBL] [Abstract][Full Text] [Related]
97. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies.
Jess T; Gamborg M; Matzen P; Munkholm P; Sørensen TI
Am J Gastroenterol; 2005 Dec; 100(12):2724-9. PubMed ID: 16393226
[TBL] [Abstract][Full Text] [Related]
98. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients.
Josselin L; Mahr A; Cohen P; Pagnoux C; Guaydier-Souquières G; Hayem G; Job-Deslandre C; Liferman F; Pourrat J; Guillevin L
Ann Rheum Dis; 2008 Sep; 67(9):1343-6. PubMed ID: 18445626
[TBL] [Abstract][Full Text] [Related]
99. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients.
Fardet L; Dupuy A; Kerob D; Levy A; Allez M; Begon E; Bachelez H; Morel P; Lebbé C
J Am Acad Dermatol; 2007 Apr; 56(4):624-8. PubMed ID: 17240478
[TBL] [Abstract][Full Text] [Related]
100. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study.
Breynaert C; Ferrante M; Fidder H; Van Steen K; Noman M; Ballet V; Vermeire S; Rutgeerts P; Van Assche G
Am J Gastroenterol; 2011 Apr; 106(4):778-85. PubMed ID: 21407184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
